Journal
Journal of Comparative Effectiveness Research
Publication Date
9-1-2023
Volume
12
Issue
9
First Page
e230036
Document Type
Open Access Publication
DOI
10.57264/cer-2023-0036
Rights and Permissions
Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023 Sep;12(9):e230036. doi: 10.57264/cer-2023-0036. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/. For full bibliographic citation, please refer to the version available at www.futuremedicine.com.
Recommended Citation
Mauch, Teri J; Chladek, Michael R; Cataland, Spero; Chaturvedi, Shruti; Dixon, Bradley P; Garlo, Katherine; Gasteyger, Christoph; Java, Anuja; Leguizamo, Jorge; Lloyd-Price, Lucy; Pham, Tan P; Symonds, Tara; Tomazos, Ioannis; and Wang, Yan, "Treatment preference and quality of life impact: Ravulizumab vs eculizumab for atypical hemolytic uremic syndrome." Journal of Comparative Effectiveness Research. 12, 9. e230036 (2023).
https://digitalcommons.wustl.edu/oa_4/2212
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
